Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study

Tycel Phillips, Mark Brunvand, Andy I. Chen, James Essell, Annalisa Chiappella, Catherine Diefenbach, Ji Cheng, David Ramies, Jamie Hirata, Franck Morschhauser, Ian W. Flinn

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)E24-E27
JournalAmerican Journal of Hematology
Issue number1
StatePublished - Jan 1 2022

ASJC Scopus subject areas

  • Hematology

Cite this